ProstateGeneID
GTR Test Accession: Help GTR000591853.2
INHERITED DISEASECANCERINHERITED DISEASE SUSCEPTIBILITY ... View more
Last updated in GTR: 2021-05-03
Last annual review date for the lab: 2024-04-03 LinkOut
At a Glance
Risk Assessment
Aplastic anemia; BAP1-related tumor predisposition syndrome; Breast and colorectal cancer, susceptibility to more...
ATM (11q22.3); BRCA1 (17q21.31); BRCA2 (13q13.1); BRIP1 (17q23.2); CHEK2 (22q12.1) more...
Molecular Genetics - Mutation scanning of the entire coding region: Next-Generation (NGS)/Massively parallel sequencing (MPS); ...
Individuals that meet NCCN criteria for Hereditary Prostate Cancer
Not provided
Not provided
Ordering Information
Offered by: Help
GeneID Lab - Advanced Molecular Diagnostics
View lab's website
View lab's test page
Specimen Source: Help
Who can order: Help
  • Genetic Counselor
  • Health Care Provider
  • Licensed Physician
  • Nurse Practitioner
  • Registered Nurse
Test Order Code: Help
PST
Contact Policy: Help
Laboratory can only accept contact from health care providers. Patients/families are encouraged to discuss genetic testing options with their health care provider.
How to Order: Help
Test service: Help
Clinical Testing/Confirmation of Mutations Identified Previously
Informed consent required: Help
Yes
Pre-test genetic counseling required: Help
Decline to answer
Post-test genetic counseling required: Help
Decline to answer
Recommended fields not provided:
Conditions Help
Total conditions: 25
Condition/Phenotype Identifier
Test Targets
Genes Help
Total genes: 18
Gene Associated Condition Germline or Somatic Allele (Lab-provided) Variant in NCBI
Methodology
Total methods: 2
Method Category Help
Test method Help
Instrument
Mutation scanning of the entire coding region
Next-Generation (NGS)/Massively parallel sequencing (MPS)
Ion Torrent Platform (Ion sphere particles - Chef System/S5XL
Sequence analysis of the entire coding region
Next-Generation (NGS)/Massively parallel sequencing (MPS)
Illumina MiniSeq
Clinical Information
Test purpose: Help
Risk Assessment
Target population: Help
Individuals that meet NCCN criteria for Hereditary Prostate Cancer
View citations (2)
  • Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Goggins M, Hutton ML, , Karlan BY, Khan S, Klein C, Kohlmann W, , Kurian AW, Laronga C, Litton JK, Mak JS, , Menendez CS, Merajver SD, Norquist BS, Offit K, Pederson HJ, Reiser G, , Senter-Jamieson L, , Shannon KM, Shatsky R, Visvanathan K, Weitzel JN, Wick MJ, Wisinski KB, Yurgelun MB, Darlow SD, Dwyer MA. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(1):77-102. doi:10.6004/jnccn.2021.0001. Epub 2021 Jan 06. PMID: 33406487.
  • ' NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®). Prostate cancer early detection. Version 2.2020 - August 24, 2020. NCCN.org '
Variant Interpretation:
What is the protocol for interpreting a variation as a VUS? Help
ACMG guidelines.

Are family members with defined clinical status recruited to assess significance of VUS without charge? Help
Yes.

Will the lab re-contact the ordering physician if variant interpretation changes? Help
Not provided.
Recommended fields not provided:
Technical Information
Availability: Help
Tests performed
Entire test performed in-house
Analytical Validity: Help
To establish analytical sensitivity and specificity, reference samples that contain both disease-associated and non-disease associated sequence variations were analyzed. Analytical sensitivity: The likelihood of the assay to detect a sequence variation when present within the analyzed genomic region (the test’s false negative rate) was established. All samples tested that have … View more
View citations (3)
Proficiency testing (PT):
Is proficiency testing performed for this test? Help
No
Recommended fields not provided:
Regulatory Approval
FDA Review: Help
Not provided
Additional Information

IMPORTANT NOTE: NIH does not independently verify information submitted to GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.